Intercept (ICPT) Announces Positive Results for Liver Drug Trial

Shares of Intercept Pharmaceuticals Inc. (ICPT) were down -32.26 or -6.98 percent to $430.00 per share in pre-market trading on Monday, after the company announced in their 10K filing late Friday that there were adverse cardiac issues connected to their experimental drug for the treatment of liver disease. The company announced on Sunday that its Read the full article... Read the rest of Intercept (ICPT) Announces Positive Results for Liver Drug Trial at InvestorGuide.com .